Compare BLLN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | ICUI |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2025 | 1992 |
| Metric | BLLN | ICUI |
|---|---|---|
| Price | $92.70 | $151.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $137.83 | ★ $179.50 |
| AVG Volume (30 Days) | 222.9K | ★ 245.2K |
| Earning Date | 12-09-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $254,136,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $98.01 | N/A |
| Revenue Next Year | $36.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 254.30 | N/A |
| 52 Week Low | $80.00 | $107.00 |
| 52 Week High | $138.70 | $165.17 |
| Indicator | BLLN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 52.99 |
| Support Level | $80.65 | $148.71 |
| Resistance Level | $87.54 | $154.79 |
| Average True Range (ATR) | 5.60 | 4.65 |
| MACD | 0.97 | -0.31 |
| Stochastic Oscillator | 88.21 | 37.28 |
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.